Overview

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Status:
Completed

Trial end date:
2023-09-22

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Clarithromycin